Kangmei Pharmaceutical (600518) Update Report: Increased Regulatory Risks and Uncertainty
Kangmei Pharmaceutical (600518): Leading Chinese herbal medicine distribution policy benefits the most
Kangmei Pharmaceutical Industry (600518): the main business is steady and optimistic about extension
Kangmei Pharmaceutical (600518) Quarterly report comments: the strong strategic plan for the third quarter is becoming increasingly clear
Comments on the semi-annual report of Kangmei Pharmaceutical Co., Ltd. (600518): rapid growth of slices and equipment Wisdom Pharmacy promotes C-end extension
Comment on Kangmei Pharmaceutical (600518): smart Pharmacy drives the Business of prepared slices to Speed up
Kangmei Pharmaceutical (600518) medium report comments: performance in line with the expected high-speed growth of prepared slices and equipment business
Kangmei Pharmaceutical (600518): it will take time to increase the pace of national expansion.
Comment on Kangmei Pharmaceutical (600518) event: 10 billion plus terminal ecosystem, traditional Chinese medicine giant takes the lead.
Deepin* Company* Kangmei Pharmaceutical (600518) Review: The high-viscosity C-end business model is becoming more and more clear
深度*公司*康美药业(600518):多线业务齐头并进
深度*公司*康美药业(600518)深度研究:从中药的一枝独秀到制造流通服务的一树繁花
康美药业(600518)一季报点评:智慧药房推动饮片增长 业绩略超预期
康美药业(600518)季报点评:C端拓展抬升1Q18销售费用
深度*公司*康美药业(600518)年报及季报点评:收入略超预期、多线业务齐头并进
康美药业(600518)一季报点评:业绩符合预期 中药饮片和医疗器械高速增长
康美药业(600518)年报点评:四季度增长强劲 龙头强者恒强
康美药业(600518)年报点评:业绩符合预期 看好公司长期成长逻辑
康美药业(600518)年报点评:饮片高基数上增长超30% 继续加大推进智慧药房
康美药业(600518)观点聚焦:新视野看智慧药房 C端平台雏形已现
No Data